摘要
目的研究紫杉醇、顺铂在进展期食管癌(EC)化疗中的临床效果及对患者血清肿瘤标记物的影响。方法以2021年1月-2024年6月上犹县人民医院收治的60例进展期EC患者为研究对象,经随机数字表法分为FP组(30例)与TP组(30例),FP组采用氟尿嘧啶+顺铂化疗方案,TP组则应用紫杉醇+顺铂化疗方案,比较两组临床效果、血清肿瘤标记物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]、毒副反应、生存质量[安德森症状评估量表中文版(MDASI-C)、食管癌患者生命质量测定量表体系(QLICD-ES)]。结果TP组肿瘤控制率(96.67%)高于FP组(83.33%)(P<0.05);两组治疗后CEA、CA19-9水平低于治疗前,且TP组CEA、CA19-9水平低于FP组(P<0.05);两组毒副反应发生率对比,差异无统计学意义(P>0.05);两组治疗后MDASI-C分数低于治疗前、QLICD-ES分数高于治疗前,且TP组MDASI-C分数低于FP组、QLICD-ES分数高于FP组(P<0.05)。结论紫杉醇、顺铂在进展期EC化疗中可发挥良好治疗作用,其临床疗效确切,可降低患者血清肿瘤标记物含量,安全性好,对患者生存质量具有积极改善效果。
Objective To study the clinical effect of paclitaxel and cisplatin in the chemotherapy of advanced esophageal cancer(EC)and its effect on serum tumor markers.Methods Sixty patients with advanced EC admitted to Shangyou County People's Hospital from January 2021 to June 2024 were divided into FP group(30 patients)and TP group(30 patients)by random number table method.FP group was treated with fluorouracil+cisplatin chemotherapy regimen,and TP group was treated with paclitaxel+cisplatin chemotherapy regimen.The clinical effects,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],toxic and side effects,quality of life[the Chinese version of the MD Anderson Symptom Assessment Scale(MDASI-C),Quality of Life Instruments for Chronic Diseases with Esophageal Cancer(QLICD-ES)]were compared between the two groups.Results The tumor control rate of TP group(96.67%)was higher than that of FP group(83.33%)(P<0.05).The levels of CEA and CA19-9 in the two groups after treatment were lower than those before treatment,and the levels of CEA and CA19-9 in the TP group were lower than those in the FP group(P<0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05).After treatment,the MDASI-C score of the two groups was lower than that before treatment,and the QLICD-ES score was higher than that before treatment,as well as the MDASI-C score of the TP group was lower than that of the FP group,and the QLICD-ES score was higher than that of the FP group(P<0.05).Conclusion Paclitaxel and cisplatin can play a good therapeutic role in the chemotherapy of advanced EC,and its clinical efficacy is definite.Meanwhile,it can reduce the content of serum tumor markers in patients with good safety,and has a positive effect on the quality of life.
作者
王志春
WANG Zhichun(Tumor Hematology Department of Shangyou County People's Hospital,Shangyou 341200,Jiangxi,China)
出处
《医学信息》
2025年第16期78-81,共4页
Journal of Medical Information
关键词
进展期食管癌
紫杉醇
顺铂
血清肿瘤标记物
生存质量
Advanced esophageal cancer
Paclitaxel
Cisplatin
Serum tumor markers
Quality of life
